PROCEPT BioRobotics (PRCT) Expected to Announce Quarterly Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is expected to be announcing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $80.7770 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. The company had revenue of $79.18 million for the quarter, compared to analysts’ expectations of $75.67 million. PROCEPT BioRobotics had a negative net margin of 30.60% and a negative return on equity of 23.73%. PROCEPT BioRobotics’s revenue was up 48.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.50) EPS. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PROCEPT BioRobotics Stock Performance

Shares of PRCT opened at $36.35 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.86 and a current ratio of 9.21. The stock has a market capitalization of $2.02 billion, a P/E ratio of -23.45 and a beta of 0.99. The company’s fifty day moving average is $37.13 and its two-hundred day moving average is $48.81. PROCEPT BioRobotics has a 1 year low of $32.11 and a 1 year high of $103.81.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on PRCT shares. Morgan Stanley dropped their price objective on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 15th. Oppenheimer raised shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Tuesday, September 2nd. Wells Fargo & Company lowered their price target on shares of PROCEPT BioRobotics from $75.00 to $58.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Stephens started coverage on shares of PROCEPT BioRobotics in a research note on Wednesday, July 9th. They set an “overweight” rating and a $70.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and a consensus price target of $67.50.

Institutional Investors Weigh In On PROCEPT BioRobotics

Large investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. grew its stake in PROCEPT BioRobotics by 100.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 100,000 shares of the company’s stock valued at $5,760,000 after acquiring an additional 50,000 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in PROCEPT BioRobotics by 31.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 95,302 shares of the company’s stock valued at $5,489,000 after acquiring an additional 23,049 shares during the last quarter. California State Teachers Retirement System grew its stake in PROCEPT BioRobotics by 1.4% in the 2nd quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock valued at $2,848,000 after acquiring an additional 693 shares during the last quarter. Intech Investment Management LLC grew its stake in PROCEPT BioRobotics by 54.4% in the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after acquiring an additional 10,002 shares during the last quarter. Finally, Militia Capital Partners LP grew its stake in PROCEPT BioRobotics by 57.1% in the 2nd quarter. Militia Capital Partners LP now owns 22,000 shares of the company’s stock valued at $1,267,000 after acquiring an additional 8,000 shares during the last quarter. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).